Bridger Management LLC increased its position in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 57.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,598,599 shares of the biotechnology company’s stock after purchasing an additional 946,086 shares during the quarter. Atara Biotherapeutics makes up 3.1% of Bridger Management LLC’s portfolio, making the stock its 16th biggest position. Bridger Management LLC owned 6.91% of Atara Biotherapeutics worth $47,035,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in the stock. ArrowMark Colorado Holdings LLC boosted its holdings in Atara Biotherapeutics by 13.4% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 3,146,820 shares of the biotechnology company’s stock worth $56,957,000 after buying an additional 371,099 shares during the last quarter. Carillon Tower Advisers Inc. bought a new position in shares of Atara Biotherapeutics during the 4th quarter valued at about $23,284,000. Neuberger Berman Group LLC lifted its holdings in shares of Atara Biotherapeutics by 15.2% during the 3rd quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock valued at $18,454,000 after purchasing an additional 147,061 shares in the last quarter. Artal Group S.A. lifted its holdings in shares of Atara Biotherapeutics by 66.7% during the 4th quarter. Artal Group S.A. now owns 1,000,000 shares of the biotechnology company’s stock valued at $18,100,000 after purchasing an additional 400,000 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Atara Biotherapeutics by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock valued at $11,842,000 after purchasing an additional 13,952 shares in the last quarter. Hedge funds and other institutional investors own 76.88% of the company’s stock.
ATRA has been the topic of several research reports. Canaccord Genuity restated a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, December 29th. ValuEngine raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Citigroup raised Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 target price on the stock in a report on Wednesday, January 3rd. BidaskClub raised Atara Biotherapeutics from a “hold” rating to a “buy” rating in a report on Thursday, January 11th. Finally, Cowen started coverage on Atara Biotherapeutics in a report on Friday, January 26th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $33.80.
Shares of Atara Biotherapeutics stock opened at $41.90 on Monday. Atara Biotherapeutics Inc has a 1 year low of $11.80 and a 1 year high of $49.90.
In other Atara Biotherapeutics news, Director Carol Giltner Gallagher sold 1,183 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $46.50, for a total value of $55,009.50. Following the completion of the transaction, the director now owns 111,286 shares of the company’s stock, valued at approximately $5,174,799. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Isaac E. Ciechanover sold 1,000 shares of the stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $46.31, for a total value of $46,310.00. Following the completion of the sale, the chief executive officer now directly owns 812,613 shares of the company’s stock, valued at approximately $37,632,108.03. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 343,797 shares of company stock valued at $10,682,763. 16.20% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This report was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://ledgergazette.com/2018/03/19/atara-biotherapeutics-inc-atra-position-boosted-by-bridger-management-llc.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.